Please use a PC Browser to access Register-Tadawul
Get It
Perspective Therapeutics Announced Updated Interim Results From Its Ongoing Phase 1/2a Trial Of [212Pb]VMT-α-NET In Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors
Perspective Therapeutics, Inc. CATX | 4.95 4.96 | -5.17% +0.20% Post |
